Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013 Aug;21(8):1472-4.
doi: 10.1038/mt.2013.160.

Immunotherapy exposes cancer stem cell resistance and a new synthetic lethality

Laszlo Radvanyi  1
Affiliations
Comment

Immunotherapy exposes cancer stem cell resistance and a new synthetic lethality

Laszlo Radvanyi. Mol Ther. 2013 Aug.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
The evolving tumor genomic and antigenic landscape and cancer stem cell resistance and vulnerability during therapy. Immunotherapy and other types of cancer therapy can debulk tumors but also put selective pressure on tumors leading to the survival and outgrowth of resistant cells (relapse) that have cancer stem cell properties or properties of cells undergoing epithelial–mesenchymal transition (EMT). However, these resistant cells (shown in red) overexpress key antigens or metabolic vulnerabilities that can be targeted by newer antigen-specific immunotherapies or drugs. These new targets can be identified by molecular analysis of this changing genomic and antigenic landscape (represented by the solid arrow across the top). Immunotherapies could thus be combined with chemotherapies either simultaneously or in succession sooner to both debulk the original tumor and eradicate any emerging resistant cells. However, although relapsed tumors can be treated to induce a secondary remission, additional resistant cells could emerge (shown as the green cells). The cancer stem cell or EMT phenotype is plastic, and these cells can differentiate through mesenchymal–epithelial transition (MET) or revert to a molecular profile similar to that of the bulk of the original tumor (indicated at the top of the diagram and by the dotted arrow in reverse). Thus, these new stem cell vulnerabilities can be transient, and sensitivity to second-line therapies based on the new molecular or antigenic profile can be rapidly lost. Intermittent dosing of different regimens may be needed to overcome this problem.
See this image and copyright information in PMC

Comment on

References

    1. Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer. 2013;49:1297–1304. - PubMed
    1. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ.et al. (2012Cancer exome analysis reveals a T-cell–dependent mechanism of cancer immunoediting Nature 482400–404. - PMC - PubMed
    1. Boisgerault N, Kottke T, Pulido J, Thompson J, Diaz RM, Rommelfanger-Konkol D.et al. (2013Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse Mol Ther 211507–1516. - PMC - PubMed
    1. Kottke T, Errington F, Pulido J, Galivo F, Thompson J, Wongthida P.et al. (2011Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors Nat Med 17854–859. - PMC - PubMed
    1. Pulido J, Kottke T, Thompson J, Galivo F, Wongthida P, Diaz RM.et al. (2012Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma Nat Biotechnol 30337–343. - PMC - PubMed

Publication types

Substances